๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Atopic Dermatitis
Clinical trial register · European Union · CTIS

Atopic Dermatitis Clinical Trials in the EU, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12490 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 25 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,490
Total on CTIS
full historical archive
741
Phase III
within the shown window
Top member states
Spain 1016 France 881 Germany 860 Italy 735 Poland 585 Netherlands 531
Narrow the registerReset

Trials for Atopic Dermatitis

11 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00Atopic Dermatitis
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia, Poland, Spain
10/09/2026
Phase II
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2025-522965-31-00Atopic Dermatitis
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase II
A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
2025-521503-43-00Atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
France, Germany, Poland, Czechia, Bulgaria
14/01/2026
Phase II
Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis compared to no treatment: A prospective, controlled, split-body study
2025-521620-29-01Atopic Dermatitis
Galenica AB
Skin and Connective Tissue Diseases
Norway, Sweden
24/11/2025
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials
2025-520771-59-00Atopic Dermatitis
F. Hoffmann-La Roche AG
Skin and Connective Tissue Diseases
Italy, Poland, Germany, Spain, France
13/11/2025
Phase II
A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)
2025-521624-30-00Atopic dermatitis
Bluefin Biomedicine Inc.
Immune System Diseases
Poland, Bulgaria, Germany, Czechia, Spain
31/10/2025
Phase II
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis
2024-520302-19-00Atopic dermatitis
Aclaris Therapeutics Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany
02/09/2025
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-europe/condition/atopic-dermatitis

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 11 of those trials with a site in Atopic Dermatitis that also match the filters currently applied.

How many recently authorised EU trials have a site in Atopic Dermatitis?

11 of the 2,500 most recently authorised trials in this register list a site in Atopic Dermatitis and match the filters applied; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Atopic Dermatitis), 11 trials
PhaseTrialsShare
Phase II11100%

Most active sponsors

Lead sponsors with the most trials (Atopic Dermatitis)
Lead sponsorTrials
Aclaris Therapeutics Inc.1
Bluefin Biomedicine Inc.1
Enveda Therapeutics Inc.1
F. Hoffmann-La Roche AG1
Galderma S.A.1
Galenica AB1
Inmagene LLC1
Novartis Pharma AG1
Pfizer Inc.1
Triveni Bio Inc.1
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.